What innovations does Thermo Fisher Scientific employ in the Dharmacon RNAi Discovery and Therapeutic Services portfolio?
We offer complete RNAi-based screening solutions to accelerate drug discovery and therapeutic development by utilizing best-in-class RNAi reagents, assay technologies and laboratory automation. The portfolio of RNAi-based services is built on an established and exceedingly well-documented history of innovation in the development of both siRNA and microRNA technologies. This has allowed us to provide the first ever siRNA library, targeting the entire human genome. Our services provide clients with access to unmatched scientific expertise and the most advanced reagents and bioinformatics tools in the field of RNAi today. Taken together, this means rapid generation of meaningful results and expert recommendations to transition screening results into drug target leads. This type of outsourcing is ideal for those pharmaceutical and biotech companies that need supplemental screening capacity, or for times when internal expertise and infrastructure are not available. What exactly does having
Related Questions
- How does Medical Discovery Management Corp., the manager of the CMDF Funds, minimize the risk of portfolio companies that fail?
- What innovations does Thermo Fisher Scientific employ in the Dharmacon RNAi Discovery and Therapeutic Services portfolio?
- How is Thermo Fisher Scientific working to help pharmaceutical and biotechnology companies to find and share information?
